Scientists from the Center for Applied Medical Research (CIMA) from the University of Navarra investigate whether cardiotrophin 1, a molecule that can be measured in blood, can be used as a diagnostic marker for hypertensive cardiopathy.
After studying the relationship of this molecule with this disease, the experts believe that cardiotrophin 1 is useful for preventing or controlling the damaging effects on the heart suffered by patients with this disease. In Spain, there are four million patients with this illness, a number that supposes fifty percent of the eight million patients with high blood pressure.
The research on this cardiovascular illness was shared today during the course of the International Congress Frontiers in Transnational Research of Cardiovascular Diseases, held in the CIMA, and in which dozens of Spanish, Germans, British and Dutch scientists participated.
Currently, these types of illnesses are the number one cause of doctor's visits, hospitalization and death worldwide. As it is foreseen that their frequency will increase in the next decades, experts propose the soonest possible application of the latest biomedical and biotechnological advances for the diagnosis, prevention and treatment of these pathologies.
Cardiotrophin 1 as it intervenes in the earliest phases of hypertensive cardiopathy, if we act on it we can prevent complications such as cardiac insufficiency, atrial fibrillation, strokes and even patient death.